The Demineralized Bone Matrix Market, estimated at USD 1.50 Bn in 2025, is expected to exhibit a CAGR of 6.4% and reach USD 2.32 Bn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Market Dynamics:
The Global Demineralized Bone Matrix Market is primarily driven by two key factors:
Rising prevalence of orthopedic diseases such as osteoarthritis and osteoporosis globally is a major driver for market growth. Osteoarthritis affects over 30 million Americans each year and is the most common cause of disability. The cases of osteoporosis are also increasing rapidly. The use of Demineralized Bone Matrix helps in bone void filling, inhibits osteoclast activity and improves bone remodeling in orthopedic surgical procedures. Secondly, increasing product approvals by regulatory bodies is expected to positively impact the market during the forecast period. For instance, in 2021, Biomedical Tissue Services received FDA approval for demineralized bone fiber putty called "DynaGraft
Increasing Volume of Orthopedic Surgeries is driving the Global Demineralized Bone Matrix Market
The growing number of orthopedic surgeries such as spinal fusion, dental grafting and trauma surgeries is one of the major drivers fueling the demand for demineralized bone matrix. According to statistics, over 1.6 million spinal fusion surgeries are performed annually in the US alone for treating spinal disorders and injuries. Demineralized bone matrix plays a vital role in bone regeneration and healing after orthopedic procedures by promoting osteoconductivity and osteogenesis. Its ability to facilitate new bone growth has increased its usage as a bone graft substitute. More complex surgeries and an aging population suffering from musculoskeletal conditions are expected to further propel the volume of orthopedic procedures, thereby boosting the DBM market.
Increasing Healthcare Expenditure in Developing Nations Creating Growth Opportunities
Rising healthcare spending, growing disposable income and improving access to healthcare facilities in developing countries is creating lucrative growth opportunities for players in the demineralized bone matrix market. As per statistics, India's healthcare sector grew at a CAGR of over 22% from 2018 to 2022. While China's healthcare expenditure rose by 9.7% year-on-year to $1.2 trillion in 2020. Simultaneously, the governments of these nations are undertaking various initiatives to strengthen their healthcare infrastructures and provide affordable treatment options to citizens. This is increasing the affordability of technologically advanced bone grafts like DBM for surgical procedures. The significant unmet need for orthopedic interventions in emerging economies will continue fueling market revenues in the coming years.
Lack of Reimbursement Policies Hindering Market Growth
The demineralized bone matrix market growth is being hindered by the lack of favorable reimbursement policies for bone grafting procedures across various countries. Unlike countries like the US which provides around 65% coverage for orthopedic products and services, reimbursement rates remain poor in most developing regions. This adversely impacts the adoption of new and expensive bone graft substitutes like DBM. Additionally, private insurance providers demonstrate reluctance in shouldering the high costs associated with orthopedic surgeries involving advanced bone grafts. With a substantial amount remaining out-of-pocket expenses for patients, the demand remains constricted especially in price-sensitive emerging nations. Establishing transparent reimbursement frameworks can help alleviate this major challenge.
Availability of Alternative Treatment Modalities Restraining Adoption
The availability of alternative bone grafting options like bonemorphogenetic proteins (BMP), synthetic bone grafts and mesenchymal stem cells (MSCs) poses significant restraint on the demineralized bone matrix industry. These counterparts provide comparable clinical outcomes to DBM and certain variants even surpass it in terms of safety, biocompatibility and osteoinductivity. Synthetic bone substitutes have gained widespread acceptance over allografts due to lower risk of disease transmission and assured supply. Moreover, the ability of third-generation grafting alternatives like stem cells to regenerate native bone tissues has heightened their demand in complex revision surgeries. Stiff competition from newer and improved treatment modalities compels DBM manufacturers to invest heavily in R&D to enhance their product portfolio, which adds to production costs.
Development of 3D-Printed Demineralized Bone Scaffolds Rich Opportunity
3D-printing technology has immense potential to revolutionize the field of reconstructive surgeries including orthopedics and dentistry. The development of customized three-dimensional demineralized bone scaffolds printed from patient-specific CT/MRI data provides a gold opportunity for market stakeholders. 3D-printed DBM scaffolds offer precise anatomical shaping and sizing required for different bone defects. Their interconnected porous architecture mimics natural bone structure to promote optimal new tissue in-growth. Several startups are currently conducting clinical research to evaluate outcomes of 3D-printed DBM grafts in spinal fusion, maxillofacial and trauma reconstruction. Their ability to regenerate complex bony structures with high precision makes them an attractive alternative to autografts and allografts. As technology matures, 3D-printed DBM scaffolds will emerge as a lucrative segment within the overall market.
Advancements in Processing Techniques Opening New Avenues
Continuous advancements in demineralized bone matrix processing techniques aim to overcome its constraints and create new revenue pools. Emerging methods like super-critical carbon dioxide processing are enabling the production of decellularized and acellular DBM grafts. Their acellular composition eliminates immunogenic.
Link - https://www.coherentmarketinsights.com/market-insight/demineralized-bone-matrix-market-4550
Key Developments:
- In October 2022, Orthofix Medical Inc has announced the full market release and first implants of Legacy Demineralized Bone Matrix (DBM), a putty used to fill voids or gaps in boney defects or traumatic injuries in the spine, pelvis, or extremities. Processed by MTF Biologics, Legacy DBM retains natural growth factors essential for bone healing.
- In October 2022, Paragon 28 Inc. introduced the V92-FC+ Cellular Bone Matrix, a moldable allograft matrix containing primitive cells, specifically designed for addressing bone defects and remodeling in the foot and ankle.
- In September 2021 Essent Biologics, a nonprofit biotechnology company, has launched its spectral demineralized bone matrix (DBM), the first human-derived DBM specifically designed for 3D bioprinting and tissue engineering research. This DBM powder, derived from adult human cortical bone, offers osteoconductive properties with osteoinductive potential.
Key Players:
Medtronic plc, Johnson & Johnson (DePuy Synthes), Zimmer Biomet, Stryker, SeaSpine, Xtant Medical, RTI Surgical, HansBioMed, Arthrex GmbH, Exactech, Inc., AlloSource, Halma (Novabone), Institut Straumann AG, Orthofix Holdings, Inc., Straumann, Synthes, Integra LifeSciences, Musculoskeletal Transplant Foundation (MTF), Bacterin International, and Osiris Therapeutics
Contact Us